SAUDI-ECONOMY-PLANNING
29.4.2024 23:03:34 CEST | Business Wire | Press release
Riyadh hosted more than 1,000 global leaders for the two-day World Economic Forum (WEF) Special Meeting in Riyadh, where leading political, economics, energy and technology figures called for clear pathways to stability, prosperity and inclusive growth opportunities in the face of rising cross-border challenges.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429767765/en/
Saudi Minister of Economy and Planning His Excellency Faisal Alibrahim announces Saudi Arabia will join the AI Governance Alliance to co-launch the ‘Inclusive AI Initiative for Growth and Development’ (Photo: AETOSWire)
The more than 1,000 participants in for the WEF Special Meeting on Global Collaboration, Growth and Energy for Development made it the highest-ever number of registrations for a WEF event hosted outside of its Annual Meeting venue in Davos Klosters, Switzerland.
The Special Meeting set the stage for the launch of several initiatives in the fields of healthcare, artificial intelligence, space and sustainability. On the final day of the meeting, chief executive officer of Moderna, Stéphane Bancel, said the American pharmaceutical company is working to have the first product for cancer on the healthcare market, potentially as early as 2025.
On the first day of the meeting, the Saudi Ministry of Health signed a memorandum of understanding with the Bill & Melinda Gates Foundation to ensure equitable access to healthcare services for all, and to deliver more vaccines against polio, measles, and other vital health services to millions of children worldwide. It was one of several agreements signed by the Foundation with the Kingdom to improve global health systems and access.
During the final plenary session, Saudi Arabia’s Minister of Economy and Planning His Excellency Faisal Alibrahim announced that the Kingdom joined the AI Governance Alliance, and will co-launch the ‘Inclusive AI Initiative for Growth and Development’, to develop solutions for AI access and adoption.
The Saudi Space Agency also announced that it will launch the Center for Space Futures in the Kingdom later this year, in collaboration with WEF. The Center will serve as a platform for public-private dialogues and foster the growth of the global space economy.
A Saudi Arabia-led Sustainability Champions Network was also launched on the sidelines of the Special Meeting to accelerate Saudi’s private sector decarbonization efforts.
Saudi Arabia also announced an extension to its collaboration with WEF’s innovation platform UpLink, with two new initiatives that focus on developing solutions to reducing emissions through the circular carbon economy and regenerating the world’s oceans through blue economy innovations.
WEF President Børge Brende hailed the Special Meeting in Riyadh a consequential gathering that drew the attendance of key global leaders including the President of Palestine, Mahmoud Abbas; United States Secretary of State, Anthony Blinken; the United Kingdom’s Foreign Secretary, David Cameron.
Leading philanthropist Bill Gates joined a session on “Bridging the Health Gap”, alongside Dr. Tedros Adhanom Ghebreyesus Director-General, World Health Organization (WHO), and Fahad bin Abdurrahman Al-Jalajel, Minister of Health, Ministry of Health of Saudi Arabia.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429767765/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom